U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Orange Book Home

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 012675

Expand all

HEXADROL (DEXAMETHASONE)
0.5MG
Marketing Status: Discontinued
Active Ingredient: DEXAMETHASONE
Proprietary Name: HEXADROL
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N012675
Product Number: 004
Approval Date: Approved Prior to Jan 1, 1982
Applicant Holder Full Name: ASPEN GLOBAL INC
Marketing Status:  Discontinued
Patent and Exclusivity Information
HEXADROL (DEXAMETHASONE)
0.75MG
Marketing Status: Discontinued
Active Ingredient: DEXAMETHASONE
Proprietary Name: HEXADROL
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.75MG
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N012675
Product Number: 007
Approval Date: Approved Prior to Jan 1, 1982
Applicant Holder Full Name: ASPEN GLOBAL INC
Marketing Status:  Discontinued
Patent and Exclusivity Information
HEXADROL (DEXAMETHASONE)
1.5MG
Marketing Status: Discontinued
Active Ingredient: DEXAMETHASONE
Proprietary Name: HEXADROL
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 1.5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N012675
Product Number: 009
Approval Date: Approved Prior to Jan 1, 1982
Applicant Holder Full Name: ASPEN GLOBAL INC
Marketing Status:  Discontinued
Patent and Exclusivity Information
HEXADROL (DEXAMETHASONE)
4MG
Marketing Status: Discontinued
Active Ingredient: DEXAMETHASONE
Proprietary Name: HEXADROL
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 4MG
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N012675
Product Number: 010
Approval Date: Approved Prior to Jan 1, 1982
Applicant Holder Full Name: ASPEN GLOBAL INC
Marketing Status:  Discontinued
Patent and Exclusivity Information
Back to Top